Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PTO user fee diversions to end after FY 1998 under budget agreement, Sen. Hatch reports.

This article was originally published in The Tan Sheet

Executive Summary

PTO USER FEE SURCHARGE TO END AFTER FY 1998 UNDER BUDGET AGREEMENT reached between congressional Republicans and the White House, Senate Judiciary Committee Chairman Orrin Hatch (R-Utah) reported at a May 7 hearing on his Omnibus Patent Act of 1997 (S 507). "I have been working with the Chairman of the Senate Budget Committee, Sen. [Pete] Domenici [R-N.M.] to make certain that the surcharge is not extended," Hatch said. "I am happy to say that the budget agreement announced last week envisions an end to the surcharge after fiscal year 1998, and I will continue to be vigilant to ensure that does not change."

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel